Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03088176
Title Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors West Cancer Center
Indications

melanoma

Therapies

Dabrafenib + Talimogene laherparepvec + Trametinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST